Amplification of MYCN is the driving oncogenic event in a subset of the most aggressive neuroblastomas; exposure to MYCN antisense oligonucleotides results in tumor growth inhibition (Burkhart et al., 2003). The gene discussed is MYCN; the disease is neoplasm.